Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Martin C. Clasby is active.

Publication


Featured researches published by Martin C. Clasby.


Tetrahedron Letters | 2000

A facile Diels–Alder route to dihydronaphthofuranones

Samuel Chackalamannil; Dario Doller; Martin C. Clasby; Yan Xia; Keith Eagen; Yan Lin; Hsingan Tsai; Andrew T. McPhail

Abstract An efficient, multigram-scale synthesis of dihydronaphthofuranone 1 using a novel aryl intramolecular Diels–Alder reaction of propargyl trans -cinnamate 8 is described. Catalytic reduction of 1 gave the cis -fused tetrahydronaphthofuranone derivative 2 .


ACS Medicinal Chemistry Letters | 2016

Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease Inhibitor.

Santhosh Francis Neelamkavil; Sony Agrawal; Thomas Bara; Chad E. Bennett; Sathesh Bhat; Dipshikha Biswas; Linda Brockunier; Nicole Buist; Duane Burnette; Mark Cartwright; Samuel Chackalamannil; Robert Chase; Mariappan V. Chelliah; Austin Chen; Martin C. Clasby; Vincent J. Colandrea; Ian W. Davies; Keith Eagen; Zhuyan Guo; Yongxin Han; John A. Howe; Charles Lee Jayne; Hubert Josien; Stacia Kargman; Karen Marcantonio; Shouwu Miao; Randy R. Miller; Andrew Nolting; Patrick A. Pinto; Murali Rajagopalan

We have been focused on identifying a structurally different next generation inhibitor to MK-5172 (our Ns3/4a protease inhibitor currently under regulatory review), which would achieve superior pangenotypic activity with acceptable safety and pharmacokinetic profile. These efforts have led to the discovery of a novel class of HCV NS3/4a protease inhibitors containing a unique spirocyclic-proline structural motif. The design strategy involved a molecular-modeling based approach, and the optimization efforts on the series to obtain pan-genotypic coverage with good exposures on oral dosing. One of the key elements in this effort was the spirocyclization of the P2 quinoline group, which rigidified and constrained the binding conformation to provide a novel core. A second focus of the team was also to improve the activity against genotype 3a and the key mutant variants of genotype 1b. The rational application of structural chemistry with molecular modeling guided the design and optimization of the structure-activity relationships have resulted in the identification of the clinical candidate MK-8831 with excellent pan-genotypic activity and safety profile.


Journal of Medicinal Chemistry | 2005

Discovery of Potent Orally Active Thrombin Receptor (Protease Activated Receptor 1) Antagonists as Novel Antithrombotic Agents

Samuel Chackalamannil; Yan Xia; William J. Greenlee; Martin C. Clasby; Dario Doller; Hsingan Tsai; Theodros Asberom; Michael Czarniecki; Ho-Sam Ahn; George Boykow; Carolyn Foster; Jacqueline Agans-Fantuzzi; Matthew Bryant; Janice Lau; Madhu Chintala


Archive | 2012

CANNABINOID RECEPTOR MODULATORS

Samuel Chackalamannil; Mariappan V. Chelliah; Martin C. Clasby; Keith Eagen; Jack D. Scott; Yuguang Wang; Yan Xia; William J. Greenlee


Journal of Medicinal Chemistry | 2007

Metabolism-based identification of a potent thrombin receptor antagonist

Martin C. Clasby; Samuel Chackalamannil; Michael Czarniecki; Dario Doller; Keith Eagen; William J. Greenlee; Grace Y. Kao; Yan Lin; Hsingan Tsai; Yan Xia; Ho-Sam Ahn; Jacqueline Agans-Fantuzzi; George Boykow; Madhu Chintala; Carolyn Foster; April Smith-Torhan; Kevin B. Alton; Matthew Bryant; Yunsheng Hsieh; Janice Lau; Jairam Palamanda


Bioorganic & Medicinal Chemistry Letters | 2006

Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonists.

Martin C. Clasby; Samuel Chackalamannil; Michael Czarniecki; Dario Doller; Keith Eagen; William J. Greenlee; Yan Lin; Hsingan Tsai; Yan Xia; Ho-Sam Ahn; Jacqueline Agans-Fantuzzi; George Boykow; Madhu Chintala; Carolyn Foster; Matthew Bryant; Janice Lau


Journal of Medicinal Chemistry | 2007

Heterotricyclic Himbacine Analogs as Potent, Orally Active Thrombin Receptor (Protease Activated Receptor-1) Antagonists

Mariappan V. Chelliah; Samuel Chackalamannil; Yan Xia; Keith Eagen; Martin C. Clasby; Xiaobang Gao; William J. Greenlee; Ho-Sam Ahn; Jacqueline Agans-Fantuzzi; George Boykow; Yunsheng Hsieh; Matthew Bryant; Jairam Palamanda; Tze-Ming Chan; David Hesk; Madhu Chintala


Archive | 2002

Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists

Samuel Chackalamannil; Mariappan V. Chelliah; Martin C. Clasby; Yan Xia


Bioorganic & Medicinal Chemistry Letters | 2007

Himbacine derived thrombin receptor antagonists: discovery of a new tricyclic core.

Martin C. Clasby; Samuel Chackalamannil; Michael Czarniecki; Dario Doller; Keith Eagen; William J. Greenlee; Yan Lin; Jayaram R. Tagat; Hsingan Tsai; Yan Xia; Ho-Sam Ahn; Jacqueline Agans-Fantuzzi; George Boykow; Madhu Chintala; Yunsheng Hsieh; Andrew T. McPhail


Archive | 2005

Constrained himbacine analogs as thrombin receptor antagonists

Mariappan V. Chelliah; Samuel Chackalamannil; Yan Xia; Martin C. Clasby; William J. Greenlee; Yuguang Wang; Enrico P. Veltri; Wenxue Wu; Michael P. Graziano; Teddy Kosoglou; Madhu Chintala

Collaboration


Dive into the Martin C. Clasby's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge